Volume 6, Issue 2, June 2018, Page: 25-30
Initial Effects of the SB Natural Anticancer Drug on the Number of NK Cells, CD4+ and CD8+ T Lymphocytes in Human Peripheral Blood
Jong-Hwa Lee, Department of Internal Medicine, Sahmyook Cancer Center, Sahmyook Seoul Hospital, Seoul, Korea; Department of Internal Medicine, Sahmyook Seoul Hospital, Seoul, Korea
Yoo-Jin Cho, Department of Internal Medicine, Sahmyook Cancer Center, Sahmyook Seoul Hospital, Seoul, Korea; Department of Internal Medicine, Sahmyook Seoul Hospital, Seoul, Korea
Myung-Sup Chae, Department of Family Medicine, Sahmyook Seoul Hospital, Seoul, Korea
Wang-Jae Lee, Department of Anatomy, College of Medicine, Seoul National University, Seoul, Korea
U-Hyun Park, Department of Medical Oncology, Kyunghee University Hospital, Seoul, Korea; Department of Internal Medicine, East-West Integrative Medicine Hospital, Wien, Austria
Euishin Edmund Kim, Department of Medical Oncology, Kyunghee University Hospital, Seoul, Korea; Department of Molecular Medicine, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea; Department of Radiological Sciences, University of California Medical Center, Irvine, USA
Received: May 24, 2018;       Accepted: Jul. 19, 2018;       Published: Aug. 14, 2018
DOI: 10.11648/j.jctr.20180602.13      View  549      Downloads  26
Abstract
Most anticancer drugs produce cytotoxicites in cancer cells, but also generate effects in normal cells that create undesirable side effects, especially for immune functioning cells which have already been suppressed by cancer invasion or biological effects. The SB natural anticancer drug is a root extract of the Pulsatilla koreana plant that has been used in Korea as an effective anticancer agent for more than 20 different malignant tumors without triggering significant adverse reactions. We investigated the effects of the SB anticancer drug on human immune cells in cancer patients. 24 consecutive patients, with histologically proven cancers, received SB drug treatments and 20 control patients did not receive SB administrations. Both groups were immunologically tested before and after their SB treatments for 14 days and then weekly for the 3rd, 4th, 5th and 6th weeks thereafter. The total number of white blood cells with differential counts including monocytes and lymphocytes were checked. Immunoassay and flow cytometry were used to analyse CD4 and CD8 T cell percentages, total cell counts with their ratios, as well as CD16/56 natural killer cell percentages and cell counts. Total white blood cell counts normalized within 10 days after the SB drug administrations. The total lymphocyte counts were slightly increased, but remained within normal parameters. CD4 and CD8 T cells, as well as CD 16/56 NK cell percentages, became normal within 10 days; their total cell counts were initially increased (26.3%, 45.2%, and 16.7%, respectively) and then became normal. The SB drug was found to be effective cytoapoptotically and was also effective for immune cell recovery in cancer patients in their initial period of the SB drug treatment. These were patients who had already had a bone marrow suppression by cancer invasion and/or prior chemotherapy.
Keywords
Initial Effects, the SB Natural Anticancer Drug, NK Cells, CD4+ and CD8+ T lymphocytes, Human Peripheral Blood
To cite this article
Jong-Hwa Lee, Yoo-Jin Cho, Myung-Sup Chae, Wang-Jae Lee, U-Hyun Park, Euishin Edmund Kim, Initial Effects of the SB Natural Anticancer Drug on the Number of NK Cells, CD4+ and CD8+ T Lymphocytes in Human Peripheral Blood, Journal of Cancer Treatment and Research. Vol. 6, No. 2, 2018, pp. 25-30. doi: 10.11648/j.jctr.20180602.13
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Hersh EM (1974): In Antineoplastic and Immunosuppressive agents. Part 1. Sartorelli AC and Johns DG (eds). New York. Springer-Verlag Inc p577.
[2]
Marsh JC (1976): The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells. A review. Cancer Res 36:1853.
[3]
Jackute J, Zemaitus M, Pranys Dand Sakalauskas R (2015) The prognostic influence of tumor infiltrating CD4 and CD8 cells in resected NSCLC. J Inflamm: 63-69.
[4]
Kang SS (1989) Saponins from the roots of Pusatilla koreana. Arch Pharm Res 12:42-47.
[5]
Kim SY and Kim SB (1994) Antitumor effect of extract of Pulsatilla koreana in vitro. J Korean Cancer Asso 26 (6):959-963.
[6]
Hwang JS and Kim SH (2001) Proliferation assay of SB injection on T and B lymphocyte in SD rat splenocytes. Biotoxtech 667-699.
[7]
Moon KS, Ji JY, Cho YJ, Lee JH, Choi MS and Kim EE (2015) Therapeutic effects of SB natural anticancer drug in 50 patients with stage IV pancreatic cancer. J Cancer Tre and Res 3 (3):42-46.
[8]
Kim Y, Bang SC, Lee JH and Ahn BZ (2004) Pulsatilla saponin D; The antitumor principle from Pulsatilla koreana. Arch Pharm Res 27: 915-918.
[9]
Kim Y, Kim SB, You YJ and Ahn BZ (2002) Deoxypodophyllotoxin; The cytotoxic and antiangiogenic component from Pusatilla koreana. Planta Medica 68:271-274.
[10]
Ogawa K, Hirai M, Katsube T, Muroyama M, Hamaguchi K, Shimakawa T et al. (2000) Suppression of cellular immunity by surgical stress. Surgery 127:329-336.
[11]
Woo JH, Baik HJ, Kim CH, Chung RK, Kim DY, Lee GY et al. (2015) Effects of propofol and desflurane on immune cell populations in breast cancer patient.. A Randomized Trial. J Korean Med Sci 30 (10):1503-1508.
[12]
Kim KC, Yook JH, Eisenbraun J, Kim BS and Huber R (2012) Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma. a randomized, controlled pilot study. BMC Complement Altern Med 12:172.
[13]
Choi JB, Lee SJ, Lee YA, Maeng HG, Lee Jk and Kang YW (2014) Reference values for peripheral blood lymphocytes subsets in a healthy Korean population. Immune Netw 14 (6):289-295.
[14]
Hang WS, Min YI, Son YS and Hong SI (1995) Peripheral blood lymphocyte subset in patients with stomach cancer. J Korean Med Sci 10 (3):164-168.
[15]
Takeuchi H, Machara Y, Tokunaga E, Koga T, Kakeji Y and Sugimach K (2001) Prognostic significance of natural killer cell activity in patients with gastric carcinoma. a multivariate analysis. Am J Gastroenterol 96 (2):574-578.
[16]
Buessing A, Stumpf C, Troeger W and Schietzel M (2007) Course of mitogen stimulated T lymphocytes in cancer patients treated with Viscum album extracts. Anticancer Res27:2903-2910.
[17]
Chung MJ, Park JY, Bang SM, Park SW and Song SY (2014) Phase II clinical trial of ex vivo-expanded cytokine induced killer cell therapy in advanced pancreatic cancer. Cancer Immunol Immunother 63:939-946.
[18]
Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras Trujillo H et al (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 109:6656-6661.
[19]
Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y et al (2015) CD47 is an adverse prognostic factor and therapeutic target in gastric cancer. Cancer Med 4:1322-1333.
[20]
Sneha S, Nagare RP, Priya SK, Sidhanth C, Pors K (2017) Therapeutic antibodies against cancer stem cells:a promising approach. Cancer Immunol Immunother 66:1-16 (review).
Browse journals by subject